



IMMUNOVIA'S LABORATORY RECEIVES CAP ACCREDITATION

LUND, Sweden – Immunovia (publ.), the pancreatic cancer diagnostics company, today announced that its laboratory in North Carolina has been awarded accreditation by the College of American Pathologists (CAP). This accreditation affirms that Immunovia's lab operations meet rigorous global standards for quality, accuracy, and patient safety.

"By choosing accreditation with CAP, Immunovia is committing to be held to the highest standards possible in clinical laboratory accreditation so that physicians and patients can be assured of the quality of the PancreaSure testing process," said Dr. Lisa Ford, Clinical Lab Director at Immunovia.

The CAP's Laboratory Accreditation Program is internationally recognized and employs on-site, peer-to-peer inspections to ensure laboratories meet stringent, high-quality standards. Immunovia's laboratory underwent the comprehensive inspection with no deficiencies identified.

"Immunovia's laboratory demonstrates leadership, innovation, and a passionate commitment to standards of excellence while providing the highest quality services, ultimately for patients," said Richard M. Scanlan, MD, FCAP, chair of the CAP's Council on Accreditation. "The CAP congratulates Immunovia's laboratory on its recent CAP Accreditation."

During the CAP accreditation process, inspectors examine the laboratory's records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management. These reviews help verify activities and reflect the most recent best practices.

For further information, please contact

Jeff Borcharding, CEO
jeff.borcharding@immunovia.com

Immunovia in brief

Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of simple blood-based testing to detect proteins and antibodies that indicate a high-risk individual has developed pancreatic cancer. Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for pancreatic cancer.

USA is the world's largest market for detection of pancreatic cancer. The Company estimates that in the USA, 1.8 million individuals are at high-risk for pancreatic cancer and could benefit from annual surveillance testing.

Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm.
For more information, please visit www.immunovia.com.

About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, visit the [CAP Newsroom](#), CAP.org and yourpathologist.org to watch pathologists at work and see the stories of the patients who trust them with their care.